In addition, the role of SREBP-1c in de novo lipogenesis and NAFLD pathogenesis has been widely recognized and makes it a potential therapeutic target for the treatment of NAFLD [20,21]. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.